natgillin/translations-raw huggingface dataset:
NAME OF THE MEDICINAL PRODUCT Zyrtec 10 mg film-coated tablets Cetirizine dihydrochloride
Zyrtec 10 mg filmsko obložene tablete [Glejte Dodatek 1 - dopolniti lokalno] cetirizinijev diklorid
Netherlands: Zyrtec
Nizozemska: Zyrtec
Central and peripheral nervous system disorders Dizziness
Splošne težave utrujenost Bolezni živčevja omotica glavobol
10 ml (equals to 2 measuring spoons) contain 10 mg of cetirizine dihydrochloride.
2 merilni žlički) vsebuje 10 mg cetirizinijevega diklorida.
Finland: Zyrtec
Finska: Zyrtec
Children aged from 2 to 6 years: 2.5 mg twice daily (5 drops twice daily).
Otroci, stari od 2 do 6 let: 2,5 mg dvakrat na dan (5 kapljic dvakrat na dan).
Accidental use of the drug by a pregnant woman should not produce any harmful effects on the foetus.
Če po pomoti vzamete zdravilo, naj to ne bi imelo škodljivega vpliva na plod, vendar pa morate jemanje zdravila nemudoma prekiniti.
Children aged from 6 to 12 years: 5 mg twice daily (a half tablet twice daily).
Otroci, stari od 6 do 12 let: 5 mg dvakrat na dan (polovica tablete dvakrat na dan)
Zyrtec 10 mg/mlTropfen oral drops, solution
Zyrtec 10 mg/mlTropfen peroralne kapljice, raztopina
Romania: Zyrtec
Romunija: Zyrtec
In adults and children aged 2 year and above, Zyrtec is indicated - for the relief of nasal and ocular symptoms of seasonal and perennial allergic rhinitis.
Odrasli in otroci, stari 2 leti in več - Cetirizin je indiciran za lajšanje nosnih in očesnih simptomov sezonskega in celoletnega alergijskega rinitisa.
Children aged from 2 to 6 years: 2.5 mg twice daily (2.5 ml oral solution twice daily (a half spoon twice daily)).
Otroci, stari od 2 do 6 let: 2,5 mg dvakrat na dan (2,5 ml peroralne raztopine dvakrat na dan (polovica merilne žličke dvakrat na dan)).
Portugal: Zyrtec
Portugalska: Zyrtec
General disorders and administration site conditions: Uncommon: asthenia, malaise Rare: oedema
Splošne težave in spremembe na mestu aplikacije: Občasni: astenija, slabo počutje Redki: edem
Nevertheless, the administration of the medicine should be discontinued.
V glavnem so težave odpravljene s prenehanjem jemanja zdravila.
10 mg film-coated tablet
10mg filmsko obložene tablete
Children aged from 6 to 12 years: 5 mg twice daily (10 drops twice daily).
Otroci, stari od 6 do 12 let: 5 mg dvakrat na dan (10 kapljic dvakrat na dan).
10 mg once daily as 10 ml oral solution (2 full measuring spoons) Children between 6 and 12 years old:
10 mg enkrat na dan v obliki 10 ml peroralne raztopine (2 polni merilni žlički).
Czech Republic: Zyrtec
Češka: Zyrtec
Dosing adjustments for adult patients with impaired renal function Group
Bolniki z zmerno do hudo ledvično okvaro
Children between 6 and 12 years old: 5 mg twice daily as a half tablet twice daily.
Otroci, stari od 6 do 12 let: 5 mg oz. pol tablete dvakrat na dan
Patients with rare hereditary problems of fructose intolerance should not take cetirizine 1 mg/ml oral solution.
Bolniki s hudo ledvično okvaro z očistkom kreatinina manj kot 10 ml/min Bolniki z redko dedno intoleranco za fruktozo ne smejo jemati tega zdravila 4.4 Posebna opozorila in previdnostni ukrepi
In adults and paediatric patients 6 year and above:
Odrasli in otroci, stari 6 let in več:
Oral drops, solution Bottle of 10 ml Bottle of 15 ml Bottle of 20 ml Bottle of 30 ml
Peroralne kapljice, raztopina Steklenička 10 ml
Poland: Zyrtec
Polska: Zyrtec
Children aged from 6 to 12 years: 5 mg twice daily (5 ml oral solution bid (a full spoon twice daily).
Otroci, stari od 6 do 12 let: 5 mg dvakrat na dan (5 ml peroralne raztopine dvakrat na dan (polna merilna žlička dvakrat na dan))
Gastro-intestinal disorders: Uncommon: diarrhoea
Bolezni prebavil: Občasni: diareja
This leaflet was last approved in {MM/YYYY}.
Navodilo je bilo odobreno [Dopolniti lokalno]
QUALITATIVE AND QUANTITATIVE COMPOSITION One ml of solution contains 10 mg cetirizine dihydrochloride, one drop of solution contains 0.5 mg cetirizine dihydrochloride
KAKOVOSTNA IN KOLIČINSKA SESTAVA Ena filmsko obložena tableta vsebuje 10 mg cetirizinijevega diklorida.
One ml (equals to 20 drops) contains 10 mg of cetirizine dihydrochloride.
20 kapljic) vsebuje 10 mg cetirizinijevega diklorida.
UCB Pharma S.A. Avenida de Barcelona 239
UCB Pharma S.A. 21, Rue de Neuilly F-92003 Nanterre
In adults and children aged 6 year and above, Zyrtec is indicated - for the relief of nasal and ocular symptoms of seasonal and perennial allergic rhinitis.
Pri odraslih in otrocih, starih 6 let in več, se zdravilo Zyrtec uporablja za: - lajšanje nosnih in očesnih simptomov sezonskega in celoletnega alergijskega rinitisa - lajšanje kronične koprivnice (kronična idiopatska urtikarija)
(other constituents), to hydroxyzine or to piperazine derivatives (closely related active substances of other medicines).
- Če ste alergični na (preobčutljivi za) zdravilno učinkovino zdravila Zyrtec, katerokoli pomožno snov (druge sestavine zdravila), hidroksizin ali derivate piperazina (blizu sorodne zdravilne učinkovine drugih zdravil).
INFORMATION IN BRAILLE Zyrtec 1 mg/ml oral solution
PODATKI V BRAILLOVI PISAVI Zyrtec 1 mg/ml peroralna raztopina
Denmark: Zyrtec
Danska: Zyrtec
Cyprus: Zyrtec
Ciper: Zyrtec
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 10 mg of cetirizine dihydrochloride
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Ena tableta vsebuje 10 mg cetirizinijevega diklorida.
Norway: Zyrtec
Norveška: Zyrtec
Gastro-intestinal system disorders Diarrhoea
Bolezni prebavil diareja
Czech Republic UCB Pharma SA (BRAINE) Chemin du Foriest
UCB Pharma SA (BRAINE) Chemin du Foriest Braine-l'Alleud B-1420 Belgija
NAME OF THE MEDICINAL PRODUCT Zyrtec 10 mg/ml oral drops, solution Cetirizine dihydrochloride
NAVODILO ZA UPORABO Zyrtec 10 mg/ml peroralne kapljice, raztopina [Glejte Dodatek 1 - dopolniti lokalno] cetirizinijev diklorid
NAME OF THE MEDICINAL PRODUCT Zyrtec 1 mg/ml oral solution Cetirizine dihydrochloride
Zyrtec 1 mg/ml peroralna raztopina [Glejte Dodatek 1 - dopolniti lokalno] cetirizinijev diklorid
GENERAL CLASSIFICATION FOR SUPPLY [To be completed nationally]
NAČIN IZDAJANJA ZDRAVILA [Dopolniti lokalno]
Menstruation is no contraindication.
Menstruacija ni kontraindikacija.
No further interaction studies have been performed.
Nadaljnjih študij medsebojnega delovanja niso izvedli.
75 patients were randomised into the study and 62 of those completed the study.
75 bolnikov je bilo randomiziranih v študijo in 62 od njih je študijo zaključilo.
Your doctor will discuss with you whether the treatment should be continued.
Z zdravnikom se boste pogovorili, ali naj se zdravljenje nadaljuje.
Open date: ……………………
Datum odprtja: ……………………
In such situations, treatment cessation should be considered.
V teh primerih je treba razmisliti o prekinitvi zdravljenja.
• need to urinate more frequently than usual
• potreba po pogostejšem uriniranju kot običajno;
In addition positive effects were observed on the voiding profile, although the observed differences were not statistically significant:
Dodatno so pozitivne učinke opazili pri profilu praznjenja, čeprav opažene razlike niso bile statistično značilne:
Dispose any remaining capsules after this period.
Po tem obdobju morebitne preostale kapsule zavrzite.
After first opening: use within 45 days.
Po prvem odprtju uporabite v 45 dneh.
: 60 % of the dose in the liver, 7.7 % in the spleen; 3 h post dosing: 60 % in the liver plus spleen, and 13 % in the bladder).
: 60 % odmerka v jetrih, 7,7 % v vranici; 3 h po odmerjanju: 60 % v jetrih in vranici ter 13 % v mehurju).
Side effects have been observed with the following frequencies:
Neželeni učinki so bili opaženi z naslednjo pogostnostjo:
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines webportal.
Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznam EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
The used scale for the investigators assessment included the categories “worse”, “no change”, “fair”, “good”, “very good”, and “excellent”.
Uporabljena lestvica za oceno preiskovalcev je vključevala kategorije „slabše“, „ni spremembe“, „sprejemljivo“, „dobro“, „zelo dobro“ in „odlično“.
The capsules should be taken with water at least 1 hour before meals or 2 hours after meals.
Kapsule je treba vzeti z vodo najmanj eno uro pred obrokom ali dve uri po obroku.
No dose adjustment is recommended for these patients.
Za te bolnike ni priporočil o prilagajanju odmerka.
• allergic reactions, increased sensitivity to light
• alergijske reakcije, povečana občutljivost na svetlobo;
• lack of blood platelets, red or white blood cells
• pomanjkanje trombocitov, rdečih ali belih krvnih celic;
Blister 21 months
pretisni omot 21 mesecev
• ringing or buzzing in the ears
• zvonjenje ali brnenje v ušesih;
EXP After first opening: use within 45 days.
EXP Po prvem odprtju uporabite v 45 dneh.
• bleeding (other than menstrual bleeding)
• če krvavite (razen menstrualne krvavitve).
Date of first authorisation: 2 June 2017
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 02. junij 2017
• bleeding, including small bleeding beneath the skin
• krvavitve, vključno z majhno krvavitvijo pod kožo;
White opaque capsules size 2.
Bele neprosojne kapsule velikosti 2.
The patients were asked whether they felt improved overall since the start of treatment, and if so, whether the improvement was “slight” 25%, “moderate “50%, “great” 75% or “complete cure” 100%.
Bolnike so vprašali, ali čutijo splošno izboljšanje od začetka zdravljenja, in če da, ali je izboljšanje „neznatno“ 25 %, „zmerno“ 50 %, „dobro“ 75 % ali „popolna ozdravitev“ 100 %.
• The other ingredients are microcrystalline cellulose, magnesium stearate, gelatin, titanium dioxide (E171).
• Druge sestavine zdravila so mikrokristalna celuloza, magnezijev stearat, želatina, titanov dioksid (E171).
Stop taking elmiron if side effects occur, until they disappear.
Prenehajte jemati zdravilo elmiron, če nastopijo neželeni učinki, vse dokler ti ne izginejo.
Take the capsules whole with one glass of water, at least 1 hour before or 2 hours after meals.
Kapsule vzemite cele s kozarcem vode najmanj eno uro pred obrokom ali dve uri po obroku.
81479 Munich GERMANY
81479 München NEMČIJA
The secondary efficacy endpoints included the investigators evaluation of improvement.
Sekundarni cilji študije učinkovitosti so vključevali oceno izboljšanja, ki so jo navedli preiskovalci.
Children and adolescents elmiron is not recommended in children under 18 years as safety and efficacy have not been established in this group.
Zdravilo elmiron ni priporočljivo pri otrocih, mlajših od 18 let, saj varnost in učinkovitost v tej skupini nista bili ugotovljeni.
Titanium dioxide (E171)
Ovoj kapsule želatina titanov dioksid (E171)
Inform your doctor or pharmacist, particularly if you use medicines that prevent blood clotting, or painkillers that reduce blood clotting.
Obvestite zdravnika ali farmacevta, zlasti če jemljete zdravila, ki preprečujejo strjevanje krvi, ali protibolečinska zdravila, ki zmanjšujejo strjevanje krvi.
What elmiron is and what it is used for 2.
Kaj je zdravilo elmiron in za kaj ga uporabljamo 2.
Patients who reported at least moderate (50%) improvement were counted as responders.
Bolniki, ki so poročali najmanj o zmernem (50-odstotnem) izboljšanju, so šteli za odzivne bolnike.
Participants who reported either of the latter two categories were defined as treatment responders.
Udeleženci, ki so poročali o eni od zadnjih dveh kategorij, so šteli za bolnike, odzivne na zdravljenje.
The primary efficacy endpoint of the study was the overall improvement as self-reported by the patient after three months of treatment.
Primarni cilj študije učinkovitosti je bilo splošno izboljšanje, o katerem so bolniki sami poročali po treh mesecih zdravljenja.
Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from available data).
Neželeni učinki so spodaj navedeni v skladu s klasifikacijo organov v sistemu MedDRA in po njihovi pogostnosti: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10 000 do < 1/1 000), zelo redki (< 1/10 000) in neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
• allergic to pentosan polysulfate sodium or any of the other ingredients of this medicine (listed in section 6)
• če ste alergični na natrijev pentozan polisulfat ali katero koli sestavino tega zdravila (navedeno v poglavju 6);
After taking the medicine it passes into the urine and attaches to the lining of the bladder, helping to form a protective layer.
Potem ko vzamete zdravilo, to zdravilo preide v urin in se veže na sluznico mehurja ter pomaga oblikovati zaščitni sloj.
PVC/Aclar-Aluminium blister with 90 (9x10) capsules.
Pretisni omot (PVC/Aclar/aluminij) z 90 (9 x 10) kapsulami.
In case of adverse reactions, treatment might be paused until the symptoms abate and treatment should be continued at the recommended dose after a critical balancing of the risks thereafter.
Pri neželenih učinkih bo zdravljenje morda treba prekiniti, dokler se simptomi ne ublažijo, nato se zdravljenje nadaljuje s priporočenim odmerkom po kritičnem ovrednotenju tveganj.
In three studies, the observed difference was clearly statistically significant.
V treh študijah je bila opažena razlika statistično značilna.
The GRA assessment was evaluated via a 7-point centred scale, in which the patients can assess their global response compared to baseline as markedly worse, moderately worse, slightly worse, no change, slightly improved, moderately improved or markedly improved.
Globalno oceno odziva so ocenjevali s 7-stopenjsko lestvico, pri kateri lahko bolniki ocenijo svoj globalni odziv v primerjavi z izhodiščem kot občutno slabši, zmerno slabši, nekoliko slabši, brez sprememb, nekoliko izboljšan, zmerno izboljšan ali občutno izboljšan.
For early detection of retinal disorders, eye examination will be performed regularly.
Za zgodnje odkrivanje bolezni mrežnice je treba redno izvajati preglede oči.
The hard capsules are white and non-transparent, provided in a plastic bottle with child resistant closure or plastic/aluminium blisters, packed in a carton.
Trde kapsule so bele in neprosojne, v plastenki z za otroke varno zaporko ali v plastičnih/aluminijastih pretisnih omotih, pakiranih v škatlo.
The safety and efficacy of pentosan polysulfate sodium in children and adolescent below 18 years has not been established.
Varnost in učinkovitost natrijevega pentozan polisulfata pri otrocih ter mladostnikih, mlajših od 18 let, nista bili dokazani.
Pharmacotherapeutic group: Urologicals, other urologicals, ATC code: G04BX15.
Farmakoterapevtska skupina: urologiki, drugi urologiki, oznaka ATC: G04BX15
Response to treatment with pentosan polysulfate sodium should be reassessed every 6 months.
Odziv na zdravljenje z natrijevim pentozan polisulfatom je treba ponovno oceniti vsakih 6 mesecev.
In healthy volunteers, a single parenteral administration of radioactively labelled pentosan polysulfate sodium leads to a progressive up-take of total radioactivity by the liver, spleen, and kidney (50 min after 1 mg/kg i.v.
Pri zdravih prostovoljcih enkratni parenteralni odmerek radioaktivno označenega natrijevega pentozan polisulfata vodi do progresivnega privzema skupne radioaktivnosti v jetrih, vranici in ledvicah (50 min po 1 mg/kg i.v.
• severe mood swings or depression
• močna nihanja razpoloženja ali depresija;
Accordingly, oral administration of pentosan polysulfate sodium 3-times daily is expected to lead to accumulation of pentosan polysulfate sodium over the first 7 days of administration (accumulation factor 5-6.7).
V skladu s tem se pričakuje, da peroralno dajanje natrijevega pentozan polisulfata trikrat dnevno povzroči kopičenje natrijevega pentozan polisulfata v prvih 7 dneh dajanja (faktor kopičenja 5-6,7).
For storage conditions after first opening of the bottle, see section 6.3.
Za pogoje shranjevanja po prvem odprtju plastenke glejte poglavje 6.3. pretisni omot
This leaflet was last revised in <{MM/YYYY}>.
Navodilo je bilo nazadnje revidirano dne <{MM/YYYY}>.
Increase of ≥ 20 cc (% pts)
Povečanje za ≥ 20 cc (% točk)
Secondary outcome measures included the O'Leary-Sant IC Symptom and Problem Index, the University of Wisconsin Symptom score, patient reported symptoms of pain/discomfort and urgency, and results of a 24-hour voiding diary.
Ukrepi sekundarnega rezultata so vključevali indeks simptomov in problemov intersticijskega cistitisa po O'Leary-Santu, lestvico simptomov univerze v Wisconsinu, simptome bolečine/nelagodja in nujnosti, o katerih so poročali bolniki, in rezultate dnevnika 24-urnega praznjenja.
• infections, flu
• okužbe, gripa;
A responder analysis based on a patientreported Global Response Assessment (GRA) after 24 weeks of treatment was defined as primary endpoint.
Analiza odzivnih bolnikov na osnovi globalne ocene odziva, o katerem so poročali bolniki po 24 tednih zdravljenja, je bila opredeljena kot primarni cilj študije.
1 capsule, 3 times daily Your doctor will assess your response to elmiron every 6 months.
Zdravnik bo ocenil vašo odzivnost na zdravilo elmiron vsakih 6 mesecev.
Total daily urine volume (cc)
Skupna dnevna količina urina (cc)
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
A. IZDELOVALEC , ODGOVOREN ZA SPROŠČANJE SERIJ
The recommended dose of pentosan polysulfate sodium is 300 mg/day taken as one 100 mg capsule orally three times daily.
Priporočeni odmerek natrijevega pentozan polisulfata je 300 mg/dan, ki se jemlje kot ena 100miligramska kapsula peroralno trikrat dnevno.
3 voids less per day (% pts)
3 praznjenja manj dnevno (% točk)
Comparison of those patients receiving pentosan polysulfate sodium with those not receiving pentosan polysulfate sodium (irrespective of treatment with oral hydroxyzine) revealed no statistically significant difference between the two group, but a trend for better efficacy was observed for the primary endpoint in those patients treated with pentosan polysulfate sodium (either alone or in combination with hydroxyzine) (20 of 59, 34%) compared to the those patients not receiving pentosan polysulfate sodium, but who might receive hydroxyzine (11 of 62, 18%, p0.064):
Primerjava bolnikov, ki so prejemali natrijev pentozan polisulfat, z bolniki, ki natrijevega pentozan polisulfata niso prejemali (neodvisno od zdravljenja s peroralnim hidroksizinom), ni pokazala statistično značilne razlike med obema skupinama, vendar je bil opažen trend boljše učinkovitosti za primarni cilj študije pri bolnikih, ki so bili zdravljeni z natrijevim pentozan polisulfatom (samostojno ali v kombinaciji s hidroksizinom) (20 od 59, 34 %), v primerjavi z bolniki, ki natrijevega pentozan polisulfata niso prejemali, morda pa so prejemali hidroksizin (11 od 62, 18 %, p = 0,064):
In case no improvement is reached 6 months after treatment initiation, treatment with pentosan polysulfate sodium should be stopped.
Če 6 mesecev po začetku zdravljenja ni napredka, je treba zdravljenje z natrijevim pentozan polisulfatom prekiniti.
Due to the weak anticoagulant effect of pentosan polysulfate sodium, elmiron must not be used in patients who actively bleed.
Zaradi šibkega antikoagulacijskega učinka natrijevega pentozan polisulfata se zdravilo elmiron ne sme uporabljati pri bolnikih, ki aktivno krvavijo.
This binding of glycosaminoglycans to the bladder mucous reduces bacterial adherence to the inner surface of the bladder and in consequence the incidence of infections is reduced as well.
Ta vezava glikozaminoglikanov na sluznico mehurja zmanjša priraščanje bakterij na notranjo površino mehurja, zato se zmanjša tudi pogostost okužb.
Pentosan polysulfate sodium is a weak anticoagulant.
Natrijev pentozan polisulfat je šibek antikoagulant.
Animal studies with respect to reproductive toxicity were not conducted.
Študij na živalih glede vpliva na sposobnost razmnoževanja niso izvedli.
What elmiron is and what it is used for elmiron is a medicine that contains the active substance pentosan polysulfate sodium.
Kaj je zdravilo elmiron in za kaj ga uporabljamo elmiron je zdravilo, ki vsebuje učinkovino natrijev pentozan polisulfat.
• headache, back pain
• glavobol, bolečine v hrbtu;
administration, the apparent plasma half-life after oral administration is in the range of 24-34 hours.
dajanju hitro izloči iz obtoka, je navidezni razpolovni čas v plazmi po peroralnem dajanju v razponu 24-34 ur.
A study in healthy subjects revealed no pharmacokinetic or pharmacodynamic interactions between therapeutic doses of warfarin and pentosan polysulfate sodium.
Študija pri zdravih osebah ni razkrila farmakokinetičnega ali farmakodinamičnega medsebojnega delovanja med terapevtskimi odmerki varfarina in natrijevega pentozan polisulfata.
Furthermore a trend for better efficacy of pentosane polysulfate sodium was observed for the patients self-assessment of an improvement of pain and urgency, despite a deviating effect observed for the evaluation of urgency via the scale.
Poleg tega so opazili trend boljše učinkovitosti natrijevega pentozan polisulfata pri samooceni bolnikov glede izboljšanja bolečine in nujnosti kljub drugačnemu učinku, ki je bil opažen pri oceni nujnosti na lestvici.
Tell your doctor immediately if you experience visual changes such as reading difficulty and slower adjustment to low or reduced light.
Zdravniku takoj povejte, če se pojavijo spremembe vida, kot so težave z branjem in počasno prilagajanje okolju z malo svetlobe ali zmanjšano svetlobo.
Name and address of the manufacturer responsible for batch release bene-Arzneimittel GmbH Herterichstr.
Ime in naslov izdelovalca, odgovornega za sproščanje serij bene-Arzneimittel GmbH Herterichstr.
A trend for better efficacy under pentosan polysulfate sodium was observed for improved sexual intercourse:
Trend boljše učinkovitosti pri uporabi natrijevega pentozan polisulfata je bil opažen pri izboljšanih spolnih odnosih:
Efficacy of treatment was evaluated based on the patient reported improvement on four typical symptoms of bladder pain syndrome: pain, urgency, frequency, and nocturia, no primary endpoint was defined.
Učinkovitost zdravljenja so ocenjevali na podlagi poročanj bolnikov o izboljšanju štirih tipičnih simptomov sindroma bolečega mehurja, tj. bolečina, nujnost, pogostost in nokturija, medtem ko primarni cilj študije ni bil določen.
• a blood clotting disorder or increased risks of bleeding, such as using a medicine that inhibits blood clotting
• če imate motnje strjevanja krvi ali povečano tveganje krvavitev ter jemljete zdravilo, ki zavira strjevanje krvi;
All studies describe very low systemic availability of unchanged pentosan polysulfate sodium after oral administration.
Vse študije opisujejo zelo nizko sistemsko razpoložljivost nespremenjenega natrijevega pentozan polisulfata po peroralnem dajanju.
Capsule content Microcrystalline cellulose Magnesium stearate
Vsebina kapsule mikrokristalna celuloza magnezijev stearat
If you forget to take elmiron
Če ste pozabili vzeti zdravilo elmiron
Do not use this medicine after the expiry date which is stated on the label and carton after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki in škatli poleg oznake „EXP“.
In all of these studies, patients reported a better subjective improvement of bladder pain syndrome under treatment with pentosan polysulfate sodium compared to placebo.
V vseh teh študijah so bolniki poročali o boljšem subjektivnem izboljšanju sindroma bolečega mehurja pri zdravljenju z natrijevim pentozan polisulfatom v primerjavi s placebom.
Visual symptoms might include complaints of reading difficulty and slow adjustment to low or reduced light environments.
Vizualni simptomi lahko vključujejo težave z branjem in počasno prilagajanje okolju z malo svetlobe ali zmanjšano svetlobo.